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Abstract
Introduction
Disease-prevention  programs  compete  with  disease- 
treatment  programs  for  scarce  resources.  This  analysis 
predicts the impact of heart disease prevention and treat-
ment  initiatives  for  Lithuania,  a  middle-income  Baltic 
country of 3.3 million people.
Methods
To perform the analysis, we used data from clinical trials, 
the Lithuanian mortality registry, the Kaunas Monitoring 
of  Trends  and  Determinants  in  Cardiovascular  Disease 
(MONICA)  register,  Kaunas  University  Hospital,  and, 
when data from Lithuania were not available, the United 
States.  We  used  the  predicted  reduction  in  all-cause 
mortality (as potentially postponable deaths) per 100,000 
people aged 35 to 64 years as our outcome measure.
Results
The number of potentially postponable deaths from risk 
factor  prevention  and  management  in  the  population 
without apparent heart disease is 556.3 (plausible range,   
282.3-878.1). The number of potentially postponable deaths 
for  people  with  stable  heart  disease  is  280.4  (plausible 
range,  90.8-521.8),  7.0  with  a  public-access  defibrillator 
program (plausible range, 3.8-8.9), and 119.0 for hospital-
ized patients (plausible range, 15.9-297.7). 
Conclusion
Although improving treatment of acute events will benefit 
individual  patients,  the  potential  impact  on  the  larger 
population  is  modest.  Only  programs  that  prevent  and 
manage risk factors can generate large declines in mortal-
ity. Significant reductions in both cardiac and noncardiac 
death  magnify  the  impact  of  risk-factor  prevention  and 
management.
Introduction
Lithuania, a country of 3.3 million in Northern Europe, 
lies on the eastern shore of the Baltic Sea, north of Poland, 
south of Latvia, and west of Belarus. It regained indepen-
dence from the Soviet Union in 1990. Having a per capita 
gross  national  income  (GNI)  about  one-quarter  that  of 
the United States, Lithuania is classified by the World 
Bank as an upper middle-income country (1). As with the 
United  States,  Canada,  and  the  countries  of  Northern 
and Eastern Europe, coronary heart disease (CHD) is the 
leading cause of decreased life expectancy among middle-
aged Lithuanians (2). Preventing chronic disease through 
lifestyle improvement is a priority in Lithuania, but priva-
tization of health services, coupled with health care costs 
that are growing at a rate far greater than that of the GNI, 
could divert resources from disease prevention (3). Because 
prevention  programs  compete  with  treatment  programs 
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for scarce resources, policy makers need evidence that allo-
cating resources to disease prevention programs will have 
the greatest effect on the population’s burden of disease 
(personal  communication  between  Lithuanian  Minister 
of  Health,  Raimondas  Šukys,  and  Vilius  Grabauskas, 
November 9, 2010).
To  document  the  potential  impact  of  public  health  and 
clinical  intervention  strategies,  we  used  a  model  that 
accounts for the entire population and is relevant to both 
public  health  and  clinical  interventions  (4).  With  this 
model, we can evaluate existing or proposed interventions 
at any point along the heart disease continuum, from pre-
vention of risk factors to treatment of advanced disease. In 
this article, we report the expected impact of interventions 
that are currently available or might be developed to pre-
vent and treat heart disease for the Lithuanian population 
aged 35 to 64 years.
Methods
We  used  the  2007  register  of  the  Kaunas  University 
Hospital Department of Cardiology for medical care data 
for hospitalized patients. Kaunas University Hospital, a 
facility  with  approximately  2,000  beds,  is  the  teaching 
hospital for the Kaunas University of Medicine. Lacking 
Lithuanian data, we used data from the United States to 
estimate service-delivery rates to ambulatory patients (4). 
The Kaunas Monitoring of Trends and Determinants in 
Cardiovascular Disease (MONICA) research protocol was 
approved by the Kaunas Medical University institutional 
review board.
Our  model  divides  the  population  into  3  prevalence 
pools: people with no apparent heart disease, people with 
symptomatic heart disease with a left ventricular ejection   
fraction (LVEF) greater than 35%, and people with symp-
tomatic heart disease with an LVEF of 35% or less (4). 
This division takes into account the marked differences in 
mortality among the pools and acknowledges that differ-
ent types of interventions are most efficacious in each of 
the 3 pools.
We  categorized  acute  cardiac  events  as  out-of-hospital 
cardiac  arrest,  acute  or  emergent  events,  and  disease 
discovered  in  the  ambulatory  setting.  We  subdivided 
acute/emergent  events  into  acute  myocardial  infarction 
with  ST-segment  elevation  (STEMI)  on  electrocardio-
gram (ECG), acute heart failure with an LVEF of 35% 
or less, acute myocardial infarction without ST segment 
elevation  (nSTEMI)  on  ECG,  and  unstable  angina  or 
other acute cardiac events. The model can account for any   
intervention that would be directed at anyone in the popu-
lation who is at risk for heart disease, has stable chronic 
heart disease, or is experiencing an acute event, because 
each person must belong to 1 of the 3 pools, and all types 
of acute events are subsumed under the 3 broad categories 
of acute events.
We selected the number of potentially postponable deaths 
(PPD) as the outcome of interest for this analysis. A simi-
lar outcome has been used to estimate the source of the 
change in death rates from heart disease in the United 
States and several other countries (5-8). In this analysis, 
we calculated the number of deaths that can be prevented 
or postponed by improving risk factors or care as follows:
PPD = (expected mortality reduction when the interven-
tion is implemented) x (mortality rate) x (1 – current 
implementation rate) x (number in population).
The analysis used the cumulative-relative-benefit approach 
of Mant and Hicks to calculate the joint effect of simulta-
neous interventions (9). This model has also been used 
to estimate the potential impact of improving care in the 
United States (4,10).
In  our  analysis,  we  used  mortality  from  all  causes,  for 
several reasons. Most intervention trials report outcomes 
in terms of total mortality. Reducing the burden of heart 
disease risk reduces total mortality and deaths from other 
chronic diseases, and using total mortality as the endpoint 
eliminates  the  possibility  that  an  intervention  simply 
results in death from a different cause rather than reduc-
ing the probability of death.
Prevalence and mortality data
We  used  the  Kaunas  Monitoring  of  Trends  and 
Determinants in Cardiovascular Disease (MONICA) reg-
istry to estimate the prevalence of heart disease, and we 
used the Lithuanian death registry as the source of death 
rates for the subpopulation without heart disease (11). We 
did not have access to accurate all-cause mortality rates 
for  the  subpopulations  with  symptomatic  heart  disease 
with an LVEF greater than 35% and symptomatic heart 
disease with an LVEF of 35% or less. Therefore, we used 
the mortality rate ratios from Olmsted County, Minnesota 
(12,13). We estimated that the risk of death for people with VOLUME 8: NO. 6
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heart disease and an LVEF greater than 35% is 2.84 times 
the risk of death for those without apparent heart disease, 
and the risk of death for people with heart disease and an 
LVEF of 35% or less is 11.02 times the risk of death for 
those without apparent heart disease.
We used published reports from clinical trials to estimate 
what the 1-year case-fatality rates for acute events would 
have been without the provision of modern treatments. 
On the basis of an epidemiologic observation (13), we esti-
mated that the LVEF is 35% or less in half the cases of 
heart failure.
Risk factor data
We used the 2001 Lithuanian MONICA registry risk fac-
tor data for the analysis (14). At least 200 men and 200 
women had been screened in every 10-year age group (35-
44 y, 45-54 y, and 55-64 y). The response rate for the sur-
vey was 62.4%. The register contains data from 625 men 
and 778 women. The survey included physical measure-
ments (blood pressure, height, body weight, and hip and 
waist circumference), blood samples for serum cholesterol 
levels, and face-to-face interviews by the research staff for 
information on smoking.
Smoking
The MONICA smoking questionnaire included questions 
about  smoking  behavior  (regular  smoker,  ex-smoker, 
never-smoker, occasional smoker), type of tobacco smoked 
(cigarettes, pipe, cigars), and number of cigarettes smoked 
per  day.  Participants  who  smoked  at  least  1  cigarette, 
cigar, or pipe per day were considered regular smokers.
Blood pressure
MONICA  uses  standard  mercury  sphygmomanometers 
for  blood  pressure  measurement.  Blood  pressure  (BP) 
was measured from the right arm of the subject after 5 
minutes of rest in a sitting position. The fifth phase of 
Korotkoff sounds was recorded as diastolic BP. The mean 
of 2 readings was used. Arterial hypertension was defined 
as a systolic blood pressure level greater than 140 mm Hg, 
a diastolic blood pressure level greater than 90 mm Hg, or 
both. Participants who had taken antihypertensive drugs 
in the last 2 weeks were classified as hypertensive regard-
less of their blood pressure level.
Sensitivity analysis
We used 95% confidence intervals, when available, to define 
a plausible range for the estimates of mortality reduction 
attributable to an intervention. Otherwise, we used ±20% 
of the expected value as the plausible range. For the plau-
sible range of the current level of implementation, we used 
±20% of the observed value. For estimates of the number 
of deaths prevented or postponed, we defined the lower 
bounds  of  the  plausible  range  by  the  following  product: 
the lower bounds of the estimates for the population size, 
expected mortality rate without intervention, and expected 
effect of the intervention and the upper bound of the cur-
rent rate of intervention. We defined the upper bounds of 
the plausible range of deaths prevented or postponed by 
the following product: the upper bounds of the estimates 
for  the  population  size,  expected  mortality  rate  without 
intervention, and expected effect of the intervention and 
the lower bound of the current rate of intervention.
Because we provided the plausible range for each of the 
values used in the calculations, the reader can estimate 
the impact of the achievable level of implementation. For 
example, the PPD associated with adequate physical activ-
ity is calculated to be 303.6 (Table 1). If the reader were to 
believe that the prevalence of physically active individuals 
could be increased by only 20 percentage points rather than 
81 percentage points, the new PPD would be 303.6 × 20/81, 
or 75.0. This PPD can be compared with the PPD for any 
other intervention. For example, the maximum plausible 
PPD associated with increasing the rate of primary angio-
plasty for all patients with a STEMI is 11.6  (Table 2).
Results
Prevalence pools
A  Lithuanian  population  of  100,000  adults  aged  35  to 
64 years would comprise 92,842 people (95% CI, 91,410-
94,274) with no apparent heart disease, 5,516 (95% CI, 
4,413-6,619)  with  symptomatic  heart  disease  with  an 
LVEF greater than 35%, and 1,642 (95% CI, 1,314-1,970) 
with symptomatic heart disease with  an LVEF of 35% 
or less. We calculated that, during 1 year, 1,112 (95% CI, 
876-1,355)  people  without  apparent  heart  disease,  188 
(95% CI, 120-271) with symptomatic heart disease and an 
LVEF greater than 35%, and 217 (95% CI, 139-312) with 
symptomatic heart disease with an LVEF of 35% or less 
would die. VOLUME 8: NO. 6
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Acute events
We  calculated  that,  in  a  given  year,  168  people  would 
have an out-of-hospital cardiac arrest, 152 would have a 
STEMI, 207 would be hospitalized for acute heart failure 
with  an  LVEF  of  35%  or  less,  and  233  would  have  an 
nSTEMI. Along with these events, 1,893 people would be 
hospitalized for unstable angina, and 253 would receive a 
new diagnosis of heart disease in the ambulatory setting 
(Table 3). The events associated with the greatest num-
ber of deaths during the ensuing year would be unstable 
angina followed by out-of-hospital cardiac arrest.
Interventions in the prevalence pools
Among the 5 interventions associated with a lower risk 
of  death  or  known  to  reduce  death  for  people  without 
apparent  heart  disease,  the  largest  PPD  is  associated 
with population levels of adequate physical activity (Table 
1).  The  analysis  predicts  that  556.3  deaths  are  poten-
tially postponable if all 5 interventions were implemented 
simultaneously. 
As with people without apparent heart disease, the largest 
PPD for patients with symptomatic heart disease and an 
LVEF greater than 35% is associated with physical activ-
ity. The composite PPD for this population pool is 114.8. 
The  largest  PPD  for  patients  with  symptomatic  heart 
disease with an LVEF of 35% or less is also associated 
with physical activity. This PPD is followed by the PPD 
associated with device therapy, smoking rates, and use 
of spironolactone, a drug used to prevent sudden death 
in  patients  with  cardiomyopathy.  The  composite  poten-
tial PPD for this population pool is 165.6. The number of 
potentially postponable deaths for people with stable heart 
disease is 280.4 (plausible range, 90.8-521.8)
Interventions at the time of acute events
On  the  basis  of  the  assumption  that  community-wide 
placement  of  automated  external  defibrillators  (AEDs) 
with bystander training does not exist, the PPD associated 
with bystander training and public access to AEDs is 7.0 
(Table 2).
The largest PPD for patients who experience a STEMI 
is  associated  with  the  rate  of  primary  angioplasty,  fol-
lowed by abstinence from tobacco. The composite PPD for 
STEMI is 8.6. Among the 7 interventions that have been 
shown  to  reduce  mortality  in  patients  hospitalized  for 
heart failure with an LVEF 35% or less, the largest PPD 
is associated with cardiac rehabilitation followed by the 
use of statins. The composite PPD associated with this 
acute event is 16.5.
Among the 8 evidence-based interventions used to treat 
patients with an nSTEMI, the largest PPD is associated 
with immediate revascularization, followed by abstinence 
from tobacco. The composite PPD for nSTEMI is 11.2.
Among  the  7  evidence-based  treatments  used  to  treat 
patients  hospitalized  for  unstable  angina  and  similar 
conditions,  the  largest  PPD  is  associated  with  cardiac 
rehabilitation and smoking cessation. The composite PPD 
for unstable angina and similar conditions is 82.7. The 
combined PPD for all hospitalized patients is 119.0.
Among the 6 evidence-based interventions used to treat 
patients with heart disease discovered in the ambulatory 
setting, the largest PPDs are associated with prescription 
of  beta  blockers,  followed  by  cardiac  rehabilitation  and 
smoking cessation. The composite PPD for heart disease 
discovered in the ambulatory setting is 3.5.
Sensitivity analysis
The  results  of  the  calculations  did  not  substantively 
change when we varied the size of the population pools, 
death rates, efficacy of intervention, and the current rates 
of intervention. The upper bound PPD for acute events 
(305.1) was less than the lower bound PPD for the preva-
lence pools (373.1). The upper bound of the PPD for imme-
diate revascularization of all patients with a STEMI or an 
nSTEMI was 27.3. The lower bound of the PPD for dietary 
change (54.7) is twice this number, and the lower bound 
of the PPD for adequate physical activity is nearly 7 times 
this number. This means that, if dietary change were only 
as effective as the lower-bound estimate and only half of 
the population adopted an adequate diet, dietary change 
would still have the same population impact as immediate 
revascularization for all patients with STEMI or nSTEMI 
under the most optimistic assumptions about revascular-
ization. By far the greatest opportunity to reduce mortality 
lies with improving risk profiles and care for people in the 
3 prevalence pools (Figure).
Discussion
Our  analysis  indicates  that  interventions  that  would VOLUME 8: NO. 6
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increase adoption of a low-risk lifestyle (not smoking, eat-
ing adequate fruits and vegetables, consuming foods high in 
omega-3 fatty acids, and obtaining adequate physical activ-
ity) and treatment of hypertension among people who are 
not known to have heart disease could potentially postpone 
more than one-third of all deaths in the Lithuanian popula-
tion aged 35 to 64 years. Improving the delivery of care and 
improving  lifestyles  for  ambulatory  patients  with  heart 
disease could potentially postpone nearly 20% of all deaths. 
Optimizing care for people experiencing an acute event or 
with newly diagnosed heart disease could potentially post-
pone 8% of all deaths at most. Less favorable assumptions 
about  prevalence,  efficacy,  mortality,  and  the  ability  to 
produce lifestyle changes do not substantively change the 
results. Risk-factor prevention and control and attention to 
improving ambulatory care for patients with heart disease 
is the strategy predicted to prevent or postpone the most 
deaths in the population; fewer than 10% of all deaths can 
be prevented or postponed by further improvements in care 
for patients hospitalized with heart disease.
This study has several limitations. Perhaps the most sub-
stantial is the lack of data specific to the Lithuanian popu-
lation. Although the risk-factor data are highly reliable 
because  they  are  based  on  carefully  collected  MONICA 
data, the only ambulatory care data available to us were 
from the United States. Clearly, Lithuanian data or data 
from  a  similar  European  state  would  have  been  more 
appropriate. Limiting the analysis to adults aged 35 to 64 
when the highest mortality rates from heart disease occur 
in an older population segment is another limitation, but 
neither risk factor nor clinical care data exist for the older 
population. These shortcomings could all be corrected with 
more complete data from Lithuania; because the analysis 
is driven by an Excel spreadsheet, it can easily be updated 
with  data  from  Lithuania  or  any  other  population.  A 
more challenging shortcoming is the unknown extent to 
which newly developed interventions can lead to healthier 
lifestyles.  Given  the  magnitude  of  the  effect  of  lifestyle 
changes on death rates, interventions that would produce 
even modest movement toward healthier lifestyles would 
have a large effect on mortality.
Although the number of clinical trials to prevent and treat 
heart disease is very large, head-to-head comparisons of 
the expected effects of different interventions that address 
the burden of heart disease are nearly nonexistent. Using 
methods similar to those used in this analysis, Capewell et 
al calculated the expected impact of treating more people 
for coronary heart disease (10). However, their analysis 
addressed  only  medical  and  surgical  interventions  and 
limited the endpoint to death from heart disease rather 
than total mortality. An analysis that uses disease-spe-
cific death rates as the outcome variable underestimates 
the impact of risk-factor change. One of the authors of 
the current analysis (T.E.K.) published an analysis of the 
predicted effectiveness of various interventions if applied 
in the United States (4). As might be expected, the results 
were similar to those of the current analysis, because both 
reports used the same intervention data, and the major 
burden of disease in both countries is chronic disease.
The implications of this analysis extend beyond the bor-
ders of Lithuania. Cardiovascular disease — heart disease 
and stroke — is the leading cause of death in the world, 
and high-tech approaches to the problem are being aggres-
sively marketed worldwide by technology and pharmaceu-
tical companies. Particularly when specialist physicians 
are  also  advocating  for  large  investments  in  high-tech 
solutions by pointing to improved outcomes in individual 
patients, policy makers may find it difficult to resist their 
arguments  for  large  investments  in  medical  technology 
and devices. We hope that access to analytic methods like 
the one used in this report can help make policy decisions 
more rational, evidence-based, and beneficial for popula-
tion health.
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Tables
Table 1. Estimated Impact of Interventions Before or Between Acute Cardiac Events, Lithuania
Population Pool/Intervention
Proportion (95% CI)a
PPD per 100,000 Population 
(95% CI)
Expected Mortality Reduction in 
the Candidate Population Current Level of Implementationb
No Apparent Heart Disease
Improved diet 0.23c (0.12-0.32) 0.0 (0.19-0.8) 13. (.-29.9)
Abstinence from tobacco 0.0d (0.9-0.1) 0.81 (0.-0.83) 10. (12.0-23.3)
Adequate physical activity 0.30e (0.2-0.36) 0.09 (0.0-0.11) 303.6 (18.6-2.8)
Increase omega-3 fatty acid consumption 0.06f (0.02-0.10) 0.1 (0.33-0.9) 2.0 (.1-93.8)
Treat hypertension 0.2g (0.20-0.30) 0.11 (0.29-0.) 3. (.6-111.2)
Composite potential 6.3 (282.3-88.1)
Heart Disease With an LVEF >35%
Aspirin 0.20h (0.16-0.2) 0.9 (0.39-0.9) 19.2 (.9-39.)
Beta blocker 0.23i (0.1-0.31) 0.62 (0.0-0.) 16.6 (.6-2.3)
Statin 0.12j (0.09-0.16) 0.1 (0.33-0.9) 13.3 (.-29.1)
Abstinence from tobacco 0.36k (0.29-0.2) 0.1 (0.6-0.) 19.8 (.2-9.1)
ACE inhibitor 0.16l (0.0-0.2) 0.66 (0.9-0.3) 10.2 (1.3-31.9)
Omega-3 fatty acids 0.20m (0.06-0.33) 0.2 (0.20-0.30) 28.6 (.1-1.)
Adequate physical activity 0.2n (0.2-0.1) 0.33 (0.26-0.0) 2.9 (18.2-11.)
Composite potential 11.8 (1.1-22.1)
 
Abbreviations: CI, confidence interval; PPD, potentially postponable deaths; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; ICD, 
implantable cardioverter-defibrillator. 
a The plausible range of the estimate is the 9% confidence interval if available and ±20% of the expected value when confidence intervals were not available. 
b All current implementation estimates are from Kottke et al (). 
c Knoops et al (21). 
d Doll and Peto (22). 
e Andersen et al (23). 
f Kottke et al (2). 
g Antikainen et al (2). 
h Anti-thrombotic Trialist Collaborative (26). 
i Freemantle et al (2). 
j Baigent et al (28). 
k Critchley et al (29). 
l Yusuf et al (30). 
m GISSI investigators (31). 
n Wannamethee et al (32). 
o Flather et al (18). 
p Pitt et al (33). 
q Belardinelli et al (3). 
r Lam et al (3).
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Population Pool/Intervention
Proportion (95% CI)a
PPD per 100,000 Population 
(95% CI)
Expected Mortality Reduction in 
the Candidate Population Current Level of Implementationb
Heart Disease With an LVEF ≤35%
Aspirin 0.20h(0.16-0.2) 0. (0.-0.66) 19. (.-1.9)
Beta blocker 0.3l (0.28-0.) 0.8 (0.68-1.00) 12.1 (0.0-.9)
ACE inhibitor 0.2o (0.1-0.3) 0.8 (0.68-1.00) .8 (0.0-3.0)
Abstinence from tobacco 0.36k (0.29-0.2) 0.1 (0.-0.8) 22.6 (6.0-6.6)
Statin 0.12j (0.09-0.16) 0.6 (0.28-0.) 1. (.6-31.6)
Spironolactone 0.30p (0.18-0.0) 0.6 (0.-0.80) 21. (.9-.9)
Adequate physical activity 0.63q (0.16-0.83) 0.33 (0.26-0.0) 91. (13.-190.)
Device therapy with ICD plus biventricular 
pacemaker
0.3r (0.20-0.60) 0.20 (0.16-0.2) . (21.1-1.3)
Composite potential 16.6 (9.-29.)
 
Abbreviations: CI, confidence interval; PPD, potentially postponable deaths; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; ICD, 
implantable cardioverter-defibrillator. 
a The plausible range of the estimate is the 9% confidence interval if available and ±20% of the expected value when confidence intervals were not available. 
b All current implementation estimates are from Kottke et al (). 
c Knoops et al (21). 
d Doll and Peto (22). 
e Andersen et al (23). 
f Kottke et al (2). 
g Antikainen et al (2). 
h Anti-thrombotic Trialist Collaborative (26). 
i Freemantle et al (2). 
j Baigent et al (28). 
k Critchley et al (29). 
l Yusuf et al (30). 
m GISSI investigators (31). 
n Wannamethee et al (32). 
o Flather et al (18). 
p Pitt et al (33). 
q Belardinelli et al (3). 
r Lam et al (3).
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Table 2. Estimated Impact of Interventions at the Time of an Acute Clinical Event, Lithuania
Clinical Event/Intervention
Proportion (95% CI)a
PPD per 100,000 Population 
(95% CI)
Expected Mortality Reduction 
in the Candidate Population
Current Level of 
Implementationb
Out-of-Hospital Cardiac Arrest
Community-wide placement of automated exter-
nal defibrillators with bystander training
0.0c (0.0 to 0.06) 0.0 .0 (3.8 to 8.9)
ST-Segment Elevation Myocardial Infarction
Aspirin 0.20d (0.16 to 0.2) 0.90 (0.2 to 1.00) 0. (0.0 to 2.8)
Beta blocker 0.0e (−0.08 to 0.15) 0.9 (0. to 1.00) 0.1 (0.0 to 1.)
ACE inhibitor 0.0f (0.02 to 11) 0.9 (0. to 1.00) 0.1 (0.0 to 1.1)
Statins 0.12g (0.09 to 0.16) 0.3 (0.8 to 0.88) 0.9 (0.2 to 2.)
Primary angioplasty 0.0h (0.0 to 0.60) 0.66 (0.3 to 0.9) . (1. to 11.6)
Abstinence from tobacco 0.36i (0.29 to 0.2) 0.1 (0. to 0.8) 2.9 (0.8 to .)
Cardiac rehabilitation 0.20j (0.0 to 0.32) 0.90 (0.2 to 1.00) 0. (0.0 to 3.)
Composite potential 8.6 (2.3 to 23.2)
Acute Heart Failure Due to Left Ventricular Systolic Dysfunction
Aspirin 0.26d (0.23 to 0.29) 0.3 (0.2 to 0.6) 3.3 (1. to 6.)
Beta blockers 0.3k (0.28 to 0.) 0.8 (0.83 to 0.89) 1.6 (0.0 to 6.0)
Spironolactone 0.30l (0.18 to 0.0) 0.69 (0.16 to 0.2) 2. (0. to .2)
ACE inhibitors 0.26m (0.1 to 0.3) 0.86 (0.8 to 0.86) 1.0 (0.0 to .3)
Statins 0.20n (0.16 to 0.2) 0.36 (0.29 to 0.3) 3. (1.6 to 6.9)
Abstinence from tobacco 0.36i (0.29 to 0.2) 0.1 (0.6 to 0.) 2.8 (0. to .3)
Cardiac rehabilitation 0.3o (.08 to.) 0.10 (.08 to.12) 8. (1.2 to 20.1)
Composite potential 16. (.9 to 3.0)
 
Abbreviations: CI, confidence interval; PPD, potentially postponable deaths; ACE, angiotensin-converting enzyme. 
a The plausible range of the estimate is the 9% confidence interval if available and +20% of the expected value when confidence intervals were not available. 
b All implementation data are from the Kaunas University Hospital records. 
c Hallstrom et al (36). 
d Anti-thrombotic Trialist Collaborative (26). 
e Freemantle et al (2). 
f ACE Inhibitor Myocardial Infarction Collaborative Group (3). 
g Baigent et al (28). 
h Hartwell et al (38). 
i Critchley et al (29). 
j Taylor et al (39). 
k Shibata et al (0). 
l Pitt et al (33). 
m Flather et al (18). 
n Foody et al (1). 
o Piepoli et al (2). 
p Clopidigel in Unstable Angina (3). 
q Ottervanger et al (). 
r Bavry et al (). 
s Kottke et al (). 
t Al-Mallah et al (6).
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Clinical Event/Intervention
Proportion (95% CI)a
PPD per 100,000 Population 
(95% CI)
Expected Mortality Reduction 
in the Candidate Population
Current Level of 
Implementationb
Non–ST-Segment Elevation Myocardial Infarction
Aspirin 0.20d (0.16 to 0.2) 0.1 (0.8 to 0.96) 1.6 (0. to .2)
Beta blockers 0.0e (−0.08 to 0.15) 0.8 (0.66 to 0.8) 0.1 (0.0 to 1.8)
Clopidogrel 0.0p (−0.08 to 0.21) 0.33 (0.28 to 0.8) 1.3 (−0.8-6.3)
ACE inhibitors 0.0f (0.02 to 0.11) 0.91(0.9 to 0.0) 0.2 (0.0 to 1.2)
IIb/IIIa inhibitors −0.10q (−0.29 to 0.14) 0.03 (0.1 to 0.9) −2.6 (−4.8 to 5.5)
Immediate revascularization 0.3r (0.23 to 0.8) 0.2 (0. to 0.6) .6 (2.8 to 1.)
Statins 0.12g (0.09 to 0.16) 0.62 (0.62 to 0.83) 1.2 (0. to 3.3)
Abstinence from tobacco 0. 36i (0.29 to 0.2) 0.1(0.6 to 0.) 2.8 (0. to .)
Cardiac rehabilitation 0.20j (0.0 to 0.32) 0.90 (0.2 to 0.36) 0. (0.0 to 3.6)
Composite potential 11.2 (−0.4 to 30.3)
Unstable Angina and Heart Disease Other Than Myocardial Infarction and Heart Failure
Aspirin 0.20d (0.16 to 0.2) 0.69 (0. to 0.83) 13.6 (3.9 to 3.)
Beta blockers 0.0e (−0.08 to 0.15) 0.8 (0.62 to 0.9) 1.9 (−0.7 to 18.6)
Clopidogrel 0.0p (−0.08 to 0.21) 0.01 (0.01 to 0.01) 15.2 (−11.1 to 68.6)
ACE inhibitors 0.0f (0.02 to 0.11) 0.8 (0.68 to 1.00) 2.3 (0.0 to 11.6)
Statins 0.12g (0.09 to 0.16) 0.6 (0. to 0.6) 11.6 (.1 to 29.1)
Abstinence from tobacco 0.36i (0.29 to 0.2) 0.1 (0. to 0.8) 22.9 (6.0 to 9.8)
Cardiac rehabilitation 0.20j (0.0 to 0.32) 0.30 (0.2 to 0.36) 30. (6.3 to 80.1)
Composite potential 82. (9.1 to 210.2)
 
Abbreviations: CI, confidence interval; PPD, potentially postponable deaths; ACE, angiotensin-converting enzyme. 
a The plausible range of the estimate is the 9% confidence interval if available and +20% of the expected value when confidence intervals were not available. 
b All implementation data are from the Kaunas University Hospital records. 
c Hallstrom et al (36). 
d Anti-thrombotic Trialist Collaborative (26). 
e Freemantle et al (2). 
f ACE Inhibitor Myocardial Infarction Collaborative Group (3). 
g Baigent et al (28). 
h Hartwell et al (38). 
i Critchley et al (29). 
j Taylor et al (39). 
k Shibata et al (0). 
l Pitt et al (33). 
m Flather et al (18). 
n Foody et al (1). 
o Piepoli et al (2). 
p Clopidigel in Unstable Angina (3). 
q Ottervanger et al (). 
r Bavry et al (). 
s Kottke et al (). 
t Al-Mallah et al (6).
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Clinical Event/Intervention
Proportion (95% CI)a
PPD per 100,000 Population 
(95% CI)
Expected Mortality Reduction 
in the Candidate Population
Current Level of 
Implementationb
Ambulatory/Incidental Presentations
Aspirin 0.2d (0.23 to 0.2) 0.69 (0.63 to 0.) 0.6 (0.2 to 1.3)
Beta blockers 0.23e (0.1 to 0.31) 0.32 (0.26 to 0.38) 1.1 (0. to 2.)
ACE inhibitors 0.13t (0.06 to 0.19) 0.0 (0.32 to 0.8) 0.6 (0.1 to 1.)
Statins 0.12g (0.09 to 0.16) 0.6 (0.2 to 0.2) 0.3 (0.1 to 0.8)
Abstinence from tobacco 0.36i (0.29 to 0.2) 0.1 (0.6 to 0.) 0.8 (0.2 to 2.0)
Cardiac rehabilitation 0.20j (0.0 to 0.32) 0.30 (0.2 to 0.36) 1.0 (0.2 to 2.)
Composite potential 3. (1.2 to .)
 
Abbreviations: CI, confidence interval; PPD, potentially postponable deaths; ACE, angiotensin-converting enzyme. 
a The plausible range of the estimate is the 9% confidence interval if available and +20% of the expected value when confidence intervals were not available. 
b All implementation data are from the Kaunas University Hospital records. 
c Hallstrom et al (36). 
d Anti-thrombotic Trialist Collaborative (26). 
e Freemantle et al (2). 
f ACE Inhibitor Myocardial Infarction Collaborative Group (3). 
g Baigent et al (28). 
h Hartwell et al (38). 
i Critchley et al (29). 
j Taylor et al (39). 
k Shibata et al (0). 
l Pitt et al (33). 
m Flather et al (18). 
n Foody et al (1). 
o Piepoli et al (2). 
p Clopidigel in Unstable Angina (3). 
q Ottervanger et al (). 
r Bavry et al (). 
s Kottke et al (). 
t Al-Mallah et al (6).
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Table 3. Estimated Annual Number of Clinical Events in Population of 100,000 Adults Aged 35 to 64 Years, Lithuania
Clinical Event
Number of Events
Case-Fatality Rate at Current 
Levels of Treatment
Deaths per Year at Current 
Levels of Treatment
n (Plausible Estimate Range)a % (95% CI) n (Plausible Estimate Range)a
Out-of-hospital cardiac arrestb 168c (13-202) 0.9d (0.9-0.96) 160 (126-193)
STEMI 12 (122-182) 0.18e (0.1-0.23) 2 (18-1)
Acute heart failure due to LVEF ≤35%f 20 (166-28) 0.13g (0.10-0.16) 2 (-0)
nSTEMI 233 (186-280) 0.12g (0.09-0.1) 2 (1-1)
Unstable angina/other heart diseaseh 1,893 (1,1-2,22) 0.12i (0.09-0.1) 220 (11-329)
Ambulatory/incidental presentation 23 (202-30) 0.03j (0.02-0.0)  (-11)
 
Abbreviations: CI, confidence interval; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection fraction; nSTEMI, acute myocardial 
infarction without ST segment elevation. 
a The plausible range of the estimate is the 9% CI, if available, and 20% of the expected value when confidence intervals were not available. 
b Treatment of out-of-hospital cardiac arrest is defined as public access to automated external defibrillators with training. 
c Centers for Disease Control and Prevention (1). 
d Nichol et al (16). 
e Baigent et al (1). 
f On the basis of Olmsted County data (13), it is estimated that half of patients with heart failure have an LVEF ≤35%. 
g Flather et al (18). 
h Unstable angina/other heart disease is defined as one or more of ICD 9-CM codes 13, 1.1-1.9, 2. 
i Peterson et al (19). 
j American Heart Association (20).